Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALZT-OP1a in Mild-Moderate ALS
NCT04428775Phase 2Terminated
- Sponsor
- AZTherapies
- Start
- Sep 2020
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in amyotrophic lateral sclerosis (ALS) (2 arms), sponsored by AZTherapies. Primary endpoint: Plasma Biomarkers at 12 weeks. Started Sep 2020; status: terminated.
02
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT04428775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04428775.